A Phase I/II Trial of Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms
Latest Information Update: 13 Jan 2025
Price :
$35 *
At a glance
- Drugs Fedratinib (Primary)
- Indications Myeloproliferative disorders
- Focus Adverse reactions; Therapeutic Use
- 09 Jan 2025 Status changed from active, no longer recruiting to completed.
- 16 Oct 2024 Status changed from recruiting to active, no longer recruiting.
- 26 Aug 2024 Planned End Date changed from 1 Nov 2025 to 1 Aug 2025.